Successful TB vaccine moves forward a... - Lung Conditions C...

Lung Conditions Community Forum

56,237 members66,863 posts

Successful TB vaccine moves forward after phase 2 trial.

2greys profile image
0 Replies

Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth’s Geisel School of Medicine and published in the journal Vaccine. The three-year trial was conducted among 650 adolescents in Tanzania, a nation with high rates of TB infection, and showed that the vaccine was safe and induced immune responses against the disease.

Tuberculosis is most common infectious disease cause of death in the world (1.5 million deaths per year compared to 1 million to date from COVID-19) and a new preventive vaccine is a major global health priority. Ford von Reyn, MD, professor of medicine at the Geisel School of Medicine and lead for the vaccine development program, explained that the trial moves the Dartmouth TB vaccine one step closer to a full Phase 3 efficacy trial against TB disease. “Our collaborators in Tanzania deserve credit for their excellent work in conducting a clinical trial to rigorous international standards and moving DAR-901 forward to Phase 3,” said Von Reyn.

geiselmed.dartmouth.edu/new...

Vaccine:

sciencedirect.com/science/a...

Written by
2greys profile image
2greys
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Tuberculosis is the forgotten pandemic relying on a 100-year-old vaccine.

By some estimates, 2 billion people are now infected worldwide, and in 2019, around 1.4 million...
2greys profile image

Phase 2/3 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and provokes immune response.

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy...
2greys profile image

Moderna Says It Plans to Start Phase 3 Trial of Covid-19 Vaccine on July 27.

The biotech company Moderna plans to start its 30,000-participant Phase 3 trial of its experimental...
2greys profile image

New Merck pneumonia vaccine OK'd in US weeks after Pfizer's

U.S. regulators have approved a new pneumonia vaccine from Merck more than a month after OK'ing an...
2greys profile image

Non tuberculosis Microbacterium. NTM.

Rebecca's story was featured in today's newsletter. I can empathize with her as I have NTM. (None...